Cooperation between chemotherapy and immune checkpoint blockade to enhance anti-tumour T cell immunity in oesophageal adenocarcinoma

Cooperation between chemotherapy and immune checkpoint blockade to enhance anti-tumour T cell immunity in oesophageal adenocarcinoma

Response rates to immune checkpoint blockade (ICB) remain low in oesophageal adenocarcinoma (OAC). Combining ICB with immunostimulatory chemotherapies to boost response rates is an attractive approach for converting ‘cold’ tumours into ‘hot’ tumours. This study profiled immune checkpoint (IC) expres...

Full description

Bibliographic Details
Main Authors: Maria Davern, Noel E. Donlon, Fiona O’ Connell, Andrew D. Sheppard, Conall Hayes, Ross King, Hugo Temperley, Christine Butler, Anshul Bhardwaj, Jenny Moore, Dara Bracken-Clarke, Claire Donohoe, Narayanasamy Ravi, John V. Reynolds, Stephen G. Maher, Melissa J. Conroy, Joanne Lysaght
Format: Article
Language:English
Published: Elsevier 2022-06-01
Series:Translational Oncology
Subjects:
PD-1
A2aR
CTLA-4
FLOT regimen
CROSS regimen
Online Access:http://www.sciencedirect.com/science/article/pii/S1936523322000687

Internet

http://www.sciencedirect.com/science/article/pii/S1936523322000687

Similar Items